Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932

被引：68

作者：

Angiolillo, Anne L. ^{[1
,2
]}

Schore, Reuven J. ^{[1
,2
]}

Kairalla, John A. ^{[3
,4
]}

Devidas, Meenakshi ^{[5
]}

Rabin, Karen R. ^{[6
]}

Zweidler-McKay, Patrick ^{[7
]}

Borowitz, Michael J. ^{[8
]}

Wood, Brent ^{[9
]}

Carroll, Andrew J. ^{[10
]}

Heerema, Nyla A. ^{[11
]}

Relling, Mary V. ^{[12
]}

Hitzler, Johann ^{[13
]}

Lane, Ashley R. ^{[1
]}

Maloney, Kelly W. ^{[14
,15
]}

Wang, Cindy

Bassal, Mylene ^{[16
]}

Carroll, William L. ^{[17
,18
]}

Winick, Naomi J. ^{[19
]}

Raetz, Elizabeth A. ^{[17
,18
]}

Loh, Mignon L. ^{[20
,21
]}

Hunger, Stephen P. ^{[22
,23
,24
]}

机构：

[1] Childrens Natl Med Ctr, Washington, DC 20010 USA

[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA

[3] Univ Florida, Coll Med, Dept Biostat, Gainesville, FL 32610 USA

[4] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Biostat, Gainesville, FL 32610 USA

[5] St Jude Childrens Res Hosp, Dept Global Pediat Med, 332 N Lauderdale St, Memphis, TN 38105 USA

[6] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA

[7] ImmunoGen Inc, Boston, MA USA

[8] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA

[9] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA

[10] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA

[11] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA

[12] St Jude Childrens Res Hosp, Memphis, TN USA

[13] Hosp Sick Children, Toronto, ON, Canada

[14] Univ Colorado, Sch Med, Childrens Hosp Colorado, Aurora, CO USA

[15] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA

[16] Childrens Hosp Eastern Ontario, Div Pediat Hematol Oncol, Ottawa, ON, Canada

[17] NYU, Langone Med Ctr, Dept Pediat, New York, NY USA

[18] NYU, Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA

[19] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[20] Univ Calif San Francisco, Benioff Childrens Hosp, Dept Pediat, San Francisco, CA 94143 USA

[21] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Inst, San Francisco, CA 94143 USA

[22] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA

[23] Univ Penn, Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA

[24] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 13期

关键词：

EVENT-FREE SURVIVAL; MAINTENANCE THERAPY; ORAL METHOTREXATE; CONTINUATION THERAPY; SYSTEMIC EXPOSURE; RELAPSE; CANCER; MERCAPTOPURINE; CHEMOTHERAPY; PHARMACOKINETICS;

D O I：

10.1200/JCO.20.00494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose:AALL0932 evaluated two randomized maintenance interventions to optimize disease-free survival (DFS) while reducing the burden of therapy in children with newly diagnosed NCI standard-risk (SR) B-acute lymphoblastic leukemia (B-ALL).Methods:AALL0932 enrolled 9,229 patients with B-ALL; 2,364 average-risk (AR) patients were randomly assigned (2 x 2 factorial design) at the start of maintenance therapy to vincristine/dexamethasone pulses every 4 (VCR/DEX4) or every 12 (VCR/DEX12) weeks, and a starting dose of weekly oral methotrexate of 20 mg/m(2) (MTX20) or 40 mg/m(2) (MTX40).Results:Five-year event-free survival and overall survival (OS) from enrollment (with 95% CIs), for all eligible and evaluable SR B-ALL patients (n = 9,226), were 92.0% (91.1% and 92.8%) and 96.8% (96.2% and 97.3%), respectively. The 5-year DFS and OS from the start of maintenance for randomly assigned AR patients were 94.6% (93.3% and 95.9%) and 98.5% (97.7% and 99.2%), respectively. The 5-year DFS and OS for patients randomly assigned to receive VCR/DEX4 (n = 1,186) versus VCR/DEX12 (n = 1,178) were 94.1% (92.2% and 96.0%) and 98.3% (97.2% and 99.4%) v 95.1% (93.3% and 96.9%) and 98.6% (97.7% and 99.6%), respectively (P = .86 and .69). The 5-year DFS and OS for AR patients randomly assigned to receive MTX20 versus MTX40 were 95.1% (93.3% and 96.8%) and 98.8% (97.9% and 99.7%) v 94.2% (92.2% and 96.1%) and 98.1% (97.0% and 99.2%), respectively (P = .92 and .89).Conclusions:The 0NCI-SR AR B-ALL who received VCR/DEX12 had outstanding outcomes despite receiving one third of the vincristine/dexamethasone pulses previously used as standard of care on Children's Oncology Group (COG) trials. The higher starting dose of MTX of 40 mg/m(2)/week did not improve outcomes when compared with 20 mg/m(2)/week. The decreased frequency of vincristine/dexamethasone pulses has been incorporated into frontline COG B-ALL trials to decrease the burden of therapy for patients and their families.

引用

页码：1437 / +

页数：18

共 46 条

[41] Hospital and home chemotherapy for children with leukemia: A randomized cross-over study
Stevens, Bonnie
Croxford, Ruth
McKeever, Patricia
Yamada, Janet
Booth, Marilyn
Daub, Stacey
Gafni, Amiram
Gammon, Janet
Greenberg, Mark
[J]. PEDIATRIC BLOOD & CANCER, 2006, 47 (03) : 285 - 292
[42] METHOTREXATE BIOAVAILABILITY AFTER ORAL AND INTRAMUSCULAR ADMINISTRATION IN CHILDREN
TERESI, ME
CROM, WR
CHOI, KE
MIRRO, J
EVANS, WE
[J]. JOURNAL OF PEDIATRICS, 1987, 110 (05) : 788 - 792
[43] GLUCOCORTICOIDS IN CLINICAL ONCOLOGY
WALSH, D
AVASHIA, J
[J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 1992, 59 (05) : 505 - 515
[44] Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-Precursor acute lymphoblastic leukemia
Winick, N
Shuster, JJ
Bowman, WP
Borowitz, M
Farrow, A
Jacaruso, D
Buchanan, GR
Kamen, BA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2803 - 2811
[45] Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children
Yetgin, S.
Olcay, L.
Dibar, E.
Conter, V.
Masera, G.
Valsecchi, M. G.
Dacou-Voutetakis, C.
Henze, I.
Loening, L.
Schrappe, M.
von Stackelberg, A.
Zimmermann, M.
Attarbaschi, A.
Gadner, H.
Mann, G.
Brandalise, S. R.
Carroll, W. L.
Devidas, M.
Gaynon, P.
Hunger, S.
Nachman, J.
Janka, G.
Stary, J.
Gelber, R. D.
Bierings, M.
Kamps, W. A.
Pieters, R.
Otten, J.
Suciu, S.
Viana, M. B.
Baruchel, A.
Ortega, J. J.
Magyarosy, E.
Perez, C.
Steinberg, D.
Tsurusawa, M.
Zintl, F.
Matsuzaki, A.
Eden, T. O. B.
Lilleyman, J. S.
Richards, S.
Steinherz, P. G.
Kochupillai, V.
de Toledo, J. S.
Appelbaum, F. R.
Campbell, M.
Cheng, C.
Pei, D.
Pui, C. H.
Nakazawa, S.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (05) : 722 - 733
[46] Longitudinal Analysis of Quality-of-Life Outcomes in Children During Treatment for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group AALL0932 Trial
Zheng, Daniel J.
Lu, Xiaomin
Schore, Reuven J.
Balsamo, Lyn
Devidas, Meenakshi
Winick, Naomi J.
Raetz, Elizabeth A.
Loh, Mignon L.
Carroll, William L.
Sung, Lillian
Hunger, Stephen P.
Angiolillo, Anne L.
Kadan-Lottick, Nina S.
[J]. CANCER, 2018, 124 (03) : 571 - 579

← 1 2 3 4 5 →